Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
Disorders arising from genetic loss of function affect hundreds of thousands of people worldwide. Many of these conditions are debilitating or lethal, and very few have any treatment options. Delivering therapeutic proteins by recombinant enzyme replacement or gene therapy has shown promise for some of these disorders, but issues related to safety, lack of efficacy, and very high dosing have limited the success of many programs. At Codexis, we use our proprietary CodeEvolver® technology platform to engineer proteins that may offer improved targeting, expression, and potency when administered as gene therapies, offering potentially improved therapeutic benefit as compared to current options.
Christopher Schmitt, Sr. Scientist II at Codexis, presented a poster at the 2023 WORLDSymposium™ highlighting work being done in the GM1 Gangliosidosis gene therapy program. The objective of the work presented was to develop a suite of cell, spheroid, and organoid-based central nervous system (CNS) models for use in drug development, including enzyme replacement and gene therapy modalities.
View poster